Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
VSTM vs ABBV vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - General
Beverages - Non-Alcoholic
VSTM vs ABBV vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - General | Beverages - Non-Alcoholic |
| Market Cap | $273M | $397.56B | $355.22B |
| Revenue (TTM) | $50M | $61.16B | $49.28B |
| Net Income (TTM) | $-194M | $4.23B | $13.70B |
| Gross Margin | 83.7% | 70.2% | 61.7% |
| Operating Margin | -344.6% | 26.7% | 29.3% |
| Forward P/E | — | 15.8x | 25.2x |
| Total Debt | $77M | $69.07B | $45.49B |
| Cash & Equiv. | $205M | $5.23B | $10.27B |
VSTM vs ABBV vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Verastem, Inc. (VSTM) | 100 | 19.9 | -80.1% |
| AbbVie Inc. (ABBV) | 100 | 232.0 | +132.0% |
| The Coca-Cola Compa… (KO) | 100 | 176.8 | +76.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VSTM vs ABBV vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VSTM is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 209.1%, EPS growth 17.5%, 3Y rev CAGR 128.4%
- Lower volatility, beta 1.64, current ratio 3.09x
- 209.1% revenue growth vs KO's 1.9%
ABBV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 43 yrs, beta 0.15, yield 2.9%
- 357.3% 10Y total return vs KO's 120.9%
- Beta 0.15, yield 2.9%, current ratio 0.67x
KO is the clearest fit if your priority is quality and efficiency.
- 27.8% margin vs VSTM's -391.2%
- 13.1% ROA vs VSTM's -91.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 209.1% revenue growth vs KO's 1.9% | |
| Value | Lower P/E (15.8x vs 25.2x) | |
| Quality / Margins | 27.8% margin vs VSTM's -391.2% | |
| Stability / Safety | Beta 0.15 vs VSTM's 1.64 | |
| Dividends | 2.9% yield, 43-year raise streak, vs KO's 2.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +20.9% vs VSTM's -34.0% | |
| Efficiency (ROA) | 13.1% ROA vs VSTM's -91.6% |
VSTM vs ABBV vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VSTM vs ABBV vs KO — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABBV is the larger business by revenue, generating $61.2B annually — 1233.4x VSTM's $50M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to VSTM's -3.9%.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $50M | $61.2B | $49.3B |
| EBITDAEarnings before interest/tax | -$170M | $24.5B | $15.5B |
| Net IncomeAfter-tax profit | -$194M | $4.2B | $13.7B |
| Free Cash FlowCash after capex | -$151M | $18.7B | $12.6B |
| Gross MarginGross profit ÷ Revenue | +83.7% | +70.2% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -3.4% | +26.7% | +29.3% |
| Net MarginNet income ÷ Revenue | -3.9% | +6.9% | +27.8% |
| FCF MarginFCF ÷ Revenue | -3.0% | +30.6% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +10.0% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +61.5% | +57.4% | +18.2% |
Valuation Metrics
ABBV leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 27.1x trailing earnings, KO trades at a 71% valuation discount to ABBV's 94.8x P/E. On an enterprise value basis, ABBV's 16.3x EV/EBITDA is more attractive than KO's 26.4x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $273M | $397.6B | $355.2B |
| Enterprise ValueMkt cap + debt − cash | $145M | $461.4B | $390.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.30x | 94.84x | 27.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.75x | 25.24x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | 16.34x | 26.36x |
| Price / SalesMarket cap ÷ Revenue | 8.83x | 6.50x | 7.41x |
| Price / BookPrice ÷ Book value/share | 4.77x | — | 10.39x |
| Price / FCFMarket cap ÷ FCF | — | 22.32x | 67.07x |
Profitability & Efficiency
KO leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-5 for VSTM. KO carries lower financial leverage with a 1.33x debt-to-equity ratio, signaling a more conservative balance sheet compared to VSTM's 1.34x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs VSTM's 4/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -4.9% | +62.1% | +41.1% |
| ROA (TTM)Return on assets | -91.6% | +3.1% | +13.1% |
| ROICReturn on invested capital | — | +23.9% | +15.8% |
| ROCEReturn on capital employed | -139.0% | +21.5% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 1.34x | — | 1.33x |
| Net DebtTotal debt minus cash | -$128M | $63.8B | $35.2B |
| Cash & Equiv.Liquid assets | $205M | $5.2B | $10.3B |
| Total DebtShort + long-term debt | $77M | $69.1B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -208.73x | 3.28x | 10.70x |
Total Returns (Dividends Reinvested)
ABBV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABBV five years ago would be worth $22,106 today (with dividends reinvested), compared to $730 for VSTM. Over the past 12 months, ABBV leads with a +20.9% total return vs VSTM's -34.0%. The 3-year compound annual growth rate (CAGR) favors ABBV at 21.0% vs VSTM's -26.4% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -45.5% | -0.5% | +20.2% |
| 1-Year ReturnPast 12 months | -34.0% | +20.9% | +17.4% |
| 3-Year ReturnCumulative with dividends | -60.2% | +77.1% | +46.9% |
| 5-Year ReturnCumulative with dividends | -92.7% | +121.1% | +63.6% |
| 10-Year ReturnCumulative with dividends | -76.2% | +357.3% | +120.9% |
| CAGR (3Y)Annualised 3-year return | -26.4% | +21.0% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.15 beta — it tends to amplify market swings less than VSTM's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.2% from its 52-week high vs VSTM's 35.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.64x | 0.15x | -0.15x |
| 52-Week HighHighest price in past year | $11.25 | $244.81 | $84.04 |
| 52-Week LowLowest price in past year | $3.55 | $181.73 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +35.0% | +91.8% | +98.2% |
| RSI (14)Momentum oscillator 0–100 | 34.1 | 63.2 | 65.7 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 4.6M | 12.6M |
Analyst Outlook
Evenly matched — ABBV and KO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VSTM as "Buy", ABBV as "Buy", KO as "Buy". Consensus price targets imply 363.2% upside for VSTM (target: $18) vs 4.6% for KO (target: $86). For income investors, ABBV offers the higher dividend yield at 2.92% vs KO's 2.47%.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.25 | $257.54 | $86.29 |
| # AnalystsCovering analysts | 19 | 41 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +2.9% | +2.5% |
| Dividend StreakConsecutive years of raises | — | 43 | 56 |
| Dividend / ShareAnnual DPS | — | $6.57 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | +0.2% |
KO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ABBV leads in 2 (Valuation Metrics, Total Returns). 1 tied.
VSTM vs ABBV vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VSTM or ABBV or KO a better buy right now?
For growth investors, Verastem, Inc.
(VSTM) is the stronger pick with 209. 1% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Verastem, Inc. (VSTM) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VSTM or ABBV or KO?
On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.
1x versus AbbVie Inc. at 94. 8x. On forward P/E, AbbVie Inc. is actually cheaper at 15. 8x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VSTM or ABBV or KO?
Over the past 5 years, AbbVie Inc.
(ABBV) delivered a total return of +121. 1%, compared to -92. 7% for Verastem, Inc. (VSTM). Over 10 years, the gap is even starker: ABBV returned +357. 3% versus VSTM's -76. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VSTM or ABBV or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
15β versus Verastem, Inc. 's 1. 64β — meaning VSTM is approximately -1212% more volatile than KO relative to the S&P 500. On balance sheet safety, The Coca-Cola Company (KO) carries a lower debt/equity ratio of 133% versus 134% for Verastem, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VSTM or ABBV or KO?
By revenue growth (latest reported year), Verastem, Inc.
(VSTM) is pulling ahead at 209. 1% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, VSTM leads at 128. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VSTM or ABBV or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -677. 6% for Verastem, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -550. 3% for VSTM. At the gross margin level — before operating expenses — VSTM leads at 82. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VSTM or ABBV or KO more undervalued right now?
On forward earnings alone, AbbVie Inc.
(ABBV) trades at 15. 8x forward P/E versus 25. 2x for The Coca-Cola Company — 9. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VSTM: 363. 2% to $18. 25.
08Which pays a better dividend — VSTM or ABBV or KO?
In this comparison, ABBV (2.
9% yield), KO (2. 5% yield) pay a dividend. VSTM does not pay a meaningful dividend and should not be held primarily for income.
09Is VSTM or ABBV or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
15), 2. 5% yield, +120. 9% 10Y return). Verastem, Inc. (VSTM) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +120. 9%, VSTM: -76. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VSTM and ABBV and KO?
These companies operate in different sectors (VSTM (Healthcare) and ABBV (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: VSTM is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock; KO is a large-cap quality compounder stock. ABBV, KO pay a dividend while VSTM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.